Luminex Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Luminex stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LMNX, but not buy additional shares or sell existing shares.
View analyst ratings for Luminex or view top-rated stocks.

Wall Street analysts have given Luminex a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Luminex wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Luminex is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Luminex.

Luminex Co. (NASDAQ:LMNX) announced its quarterly earnings data on Wednesday, May, 5th. The medical instruments supplier reported $0.19 earnings per share for the quarter, topping analysts' consensus estimates of $0.15 by $0.04. The medical instruments supplier earned $110.69 million during the quarter, compared to the consensus estimate of $110.11 million. Luminex had a net margin of 5.39% and a trailing twelve-month return on equity of 4.66%.
View Luminex's earnings history.

Luminex's stock was trading at $27.11 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, LMNX shares have increased by 35.7% and is now trading at $36.79.
View which stocks have been most impacted by COVID-19.

Luminex announced a quarterly dividend on Thursday, May 20th. Shareholders of record on Thursday, June 17th will be paid a dividend of $0.10 per share on Thursday, July 8th. This represents a $0.40 annualized dividend and a yield of 1.09%. The ex-dividend date is Wednesday, June 16th.
View Luminex's dividend history.

Luminex pays an annual dividend of $0.40 per share and currently has a dividend yield of 1.08%. Luminex does not yet have a strong track record of dividend growth. The dividend payout ratio of Luminex is 125.00%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, Luminex will have a dividend payout ratio of 33.61% next year. This indicates that Luminex will be able to sustain or increase its dividend.
View Luminex's dividend history.

3 brokerages have issued 1 year price targets for Luminex's shares. Their forecasts range from $37.00 to $37.00. On average, they expect Luminex's share price to reach $37.00 in the next twelve months. This suggests a possible upside of 0.6% from the stock's current price.
View analysts' price targets for Luminex or view top-rated stocks among Wall Street analysts.

53 employees have rated Luminex CEO Nachum “Homi” Shamir on Glassdoor.com. Nachum “Homi” Shamir has an approval rating of 87% among Luminex's employees.

Some companies that are related to Luminex include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), Charles River Laboratories International (CRL), PerkinElmer (PKI), Bio-Techne (TECH), Bruker (BRKR), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all of LMNX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include NVIDIA (NVDA), Baidu (BIDU), Cisco Systems (CSCO), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Micron Technology (MU), Square (SQ), Marvell Technology (MRVL), AbbVie (ABBV) and CRISPR Therapeutics (CRSP).

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Luminex's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (17.54%), RGM Capital LLC (6.09%), Dimensional Fund Advisors LP (3.60%), Copeland Capital Management LLC (3.03%), Goldman Sachs Group Inc. (2.56%) and Neuberger Berman Group LLC (1.92%). Company insiders that own Luminex stock include Charles J Collins, G Walter Loewenbaum II, Harriss T Currie, Nachum Shamir, Nancy Fairchild, Randall Myers, Richard W Rew II and Stephen L Eck.
View institutional ownership trends for Luminex.

LMNX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Acadian Asset Management LLC, Dimensional Fund Advisors LP, Man Group plc, Intrinsic Edge Capital Management LLC, Cubist Systematic Strategies LLC, AQR Capital Management LLC, and Barclays PLC. Company insiders that have sold Luminex company stock in the last year include G Walter Loewenbaum II, Harriss T Currie, Nachum Shamir, Nancy Fairchild, and Richard W Rew II.
View insider buying and selling activity for Luminex or view top insider-selling stocks.

LMNX stock was purchased by a variety of institutional investors in the last quarter, including Brookfield Asset Management Inc., Point72 Asset Management L.P., Tamarack Advisers LP, JPMorgan Chase & Co., Pentwater Capital Management LP, RGM Capital LLC, Eversept Partners LP, and BlackRock Inc.. Company insiders that have bought Luminex stock in the last two years include G Walter Loewenbaum II, Nachum Shamir, and Stephen L Eck.
View insider buying and selling activity for Luminex or or view top insider-buying stocks.

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LMNX stock can currently be purchased for approximately $36.79.

Luminex has a market capitalization of $1.74 billion and generates $417.40 million in revenue each year. The medical instruments supplier earns $15.17 million in net income (profit) each year or $0.32 on an earnings per share basis.

Luminex employs 1,325 workers across the globe.

The official website for Luminex is www.luminexcorp.com.

Luminex is headquartered at 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727.

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]